FORM 3

(Print or Type Responses)

Person *

Bal Bhajanjit

C/O AMEDICA

(Last)

1. Name and Address of Reporting

(First)

(Middle)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Weekington, D.C. 20540

Washington, D.C. 20549

OMB APPROVAL OMB 3235Number: 0104 Estimated average burden hours per response... 0.5

5. If Amendment, Date Original

Filed (Month/Day/Year)

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Statement

02/12/2014

(Month/Day/Year)

2. Date of Event Requiring | 3. Issuer Name and Ticker or Trading Symbol

Person(s) to Issuer

AMEDICA Corp [AMDA]

4. Relationship of Reporting

Γ		-	(Check all applicable) _X_ Director 10% Owner Officer (give Other (specify				
)		<u>ti</u>	tle below)	below)	6. Indivi Filing(Ch	dual or Joint/Group leck Applicable Line) filed by One Reporting Person lied by More than One Reporting	
)	Table I - Non-Derivative Securities Beneficially Owned						
1.Title of Security (Instr. 4)		2. Amount of Securities Beneficially Owned (Instr. 4)		Ownership	1		
	58	1 (1)		D			
respond t to respond	to the col	lection of i	nformation splays a cu	contained in	n this form are OMB control		
2. Date Exercisable and Expiration Date				4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
Date Exercisable		Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)		
<u>(2)</u>	<u>(2)</u>	Common Stock	1,454	\$ <u>(2)</u>	D		
<u>(3)</u>	<u>(3)</u>	Common Stock	17,743 (3)	\$ (3)	D		
<u>(4)</u>	<u>(4)</u>	Common Stock	4,347 (4)	\$ (4)	D		
<u>(5)</u>	<u>(5)</u>	Common Stock	7,837 <u>(5)</u>	\$ <u>(5)</u>	D		
<u>(6)</u>	<u>(6)</u>	Common Stock	3,967 (6)	\$ <u>(6)</u>	D		
<u>(7)</u>	(7)	Common Stock	18,750 (7)	\$ (7)	D		
<u>(8)</u>	<u>(8)</u>	Common Stock	3,200 (8)	\$ <u>(8)</u>	D		
	for each class or respond to respond to respond to to respond to the ecurities Ber 2. Date Exercisable Exercisable (2) (3) (4) (5) (6) (7)	for each class of securities Beneficially (2) 2. Date Exercisable and Expiration Date (Month/Day/Year) Date Exercisable Expiration Date (1) (2) (2) (2) (3) (3) (4) (4) (4) (5) (5) (5) (6) (6) (6) (7) (7)	Table I - Non 2. Amount of S Beneficially Ox (Instr. 4) 581 (1) for each class of securities beneficial to respond to the collection of into respond unless the form discrete the form discre	Table I - Non-Derivati 2. Amount of Securities Beneficially Owned (Instr. 4) 581 (1) for each class of securities beneficially owned defection of information to respond unless the form displays a curities Beneficially Owned (e.g., puts, calls, variety) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) Date Exercisable Expiration Date (Month/Day/Year) Common Stock (2) (2) (2) Common Stock (3) (4) (4) (4) Common Stock (5) (6) (6) Common Stock (7) (7) Common Stock (8) (8) (8) Common Stock (8)	Table I - Non-Derivative Securities 2. Amount of Securities Beneficially Owned (Instr. 4) 581 (I) To reach class of securities beneficially owned directly or indirect (I) (Instr. 5) To respond to the collection of information contained in the respond unless the form displays a currently valid securities Beneficially Owned (e.g., puts, calls, warrants, option to respond unless the form displays a currently valid securities Beneficially Owned (e.g., puts, calls, warrants, option to respond unless the form displays a currently valid securities Beneficially Owned (e.g., puts, calls, warrants, option to respond unless the form displays a currently valid securities Underlying Derivative Security (Instr. 4) Date Expiration Date Title Amount or Number of Shares (2) (2) (2) Common Stock 1,454 \$ (2) (3) (3) Common Stock 17,743 (3) \$ (3) (4) (4) Common Stock 7,837 (5) \$ (5) (6) (6) Common Stock 7,837 (5) \$ (5) Common Stock 7,837 (5) \$ (6) (7) (7) Common Stock 18,750 (7) \$ (7) (8) \$ (8) Common Stock \$ (8) Common Stock \$ (8) \$ (8)	Table I - Non-Derivative Securities Beneficially Owned (Instr. 4) Table I - Non-Derivative Securities Beneficially Owned (Instr. 4) Table I - Non-Derivative Securities Beneficially Owned (Instr. 4) Table I - Non-Derivative Securities Beneficially Owned (Instr. 5) Table I - Non-Derivative Securities Beneficially Owned (Instr. 5) Table I - Non-Derivative Securities Beneficially Owned (Instr. 5) Table I - Non-Derivative Securities Beneficially Owned (Instr. 4) Table I - Non-Derivative Securities Beneficially Owned (Instr. 4) To respond to the collection of information contained in this form are to respond unless the form displays a currently valid OMB control or Exercise (Month/Day/Year) To respond to the collection of information contained in this form are to respond unless the form displays a currently valid OMB control or Exercise (Month/Day/Year) Table I - Non-Derivative Security of Underlying (Instr. 5) To reach class of securities beneficially owned directly or indirectly. To respond to the collection of information contained in this form are to respond unless the form displays a currently valid OMB control or Exercise (Month/Day/Year) Table I - Non-Derivative Security of Underlying (Instr. 5) To respond to the collection of information contained in this form are to respond unless the form displays a currently valid OMB control or Exercise (Price of Derivative Security: Securi	

Reporting Owners

Reporting Owner Name / Address		Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Bal Bhajanjit C/O AMEDICA CORPORATION, 1885 WEST 2100 SALT LAKE CITY, UT 84119	X					

Signatures

/s/ Jonathan Ursprung		02/12/2014		
**Signature of Reporting Person		Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Consists of 581 restricted stock units, each of which represents a contingent right to receive one share of Issuer's common stock. The
- (1) restricted stock units vest on the earlier of a change in control or the date of the expiration of the lock up period imposed on the Reporting Person after completion of the closing of the underwritten initial public offering of shares of the Issuer's Common Stock.
- (2) Consists of a warrant to purchase 1,454 shares of Common Stock at an exercise price of \$25.77 per share of Common Stock exercisable at any time and expiring on August 30, 2018.
- Upon the closing of the Issuer's initial public offering of shares of its Common Stock, each share of Series B-1 Convertible Preferred

 Stock will convert into 1.5244 shares of the Issuer's Common Stock pursuant to the terms of the Certificate of Designation for Series B-1 Convertible Preferred Stock of the Issuer. This conversion is reflected in column 3 in the amount of securities underlying the derivative securities.
- Upon the closing of the Issuer's initial public offering of shares of its Common Stock, each share of Series C Convertible Preferred

 Stock will convert into 1.1206 shares of the Issuer's Common Stock pursuant to the terms of the Certificate of Designation for Series C Convertible Preferred Stock of the Issuer. This conversion is reflected in column 3 in the amount of securities underlying the derivative securities.
- Upon the closing of the Issuer's initial public offering of shares of its Common Stock, each share of Series D-1 Convertible Preferred

 (5) Stock will convert into 1.6834 shares of the Issuer's Common Stock pursuant to the terms of the Certificate of Designation for Series D-1 Convertible Preferred Stock of the Issuer. This conversion is reflected in column 3 in the amount of securities underlying the derivative securities
- Upon the closing of the Issuer's initial public offering of shares of its Common Stock, each share of Series E Convertible Preferred

 (6) Stock will convert into 1.1363 shares of the Issuer's Common Stock pursuant to the terms of the Certificate of Designation for Series E Convertible Preferred Stock of the Issuer. This conversion is reflected in column 3 in the amount of securities underlying the derivative securities.
- Upon the closing of the Issuer's initial public offering of shares of its Common Stock, each share of Series F Convertible Preferred

 (7) Stock will convert into 6.44370 shares of the Issuer's Common Stock pursuant to the terms of the Certificate of Designation for Series F Convertible Preferred Stock of the Issuer. This conversion is reflected in column 3 in the amount of securities underlying the derivative
 - Includes options to purchase 194 shares of Common Stock at an exercise price of \$15.46 per share, exercisable at any time and expiring December 20, 2015; options to purchase 388 shares of Common Stock at an exercise price of \$25.77 per share, exercisable at any time and expiring February 12, 2016; options to purchase 291 shares of Common Stock at an exercise price of \$25.77 per share, exercisable at
- (8) any time and expiring December 11, 2016; options to purchase 388 shares of Common Stock at an exercise price of \$47.68 per share, exercisable at any time and expiring December 19, 2017; options to purchase 1551 shares of Common Stock at an exercise price of \$25.77 per share, exercisable on or after at any time and expiring March 15, 2022; and options to purchase 388 shares of Common Stock at an exercise price of \$25.77 per share, exercisable at any time and expiring March 15, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints Kevin Ontiveros, the Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary of Amedica Corporation (the "Company"), Amy N. Wood, Corporate Paralegal for the Company, and Daniel Kajunski, Anthony Hubbard, Kanasha Herbert, Jonathan Ursprung and Caroline Gammill, each of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, forms and authentication documents for EDGAR Filing Access;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents:
- (3) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (4) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney- in fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact, on behalf of the undersigned pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 2nd day of Dec, 2013.

/s/ Bhajanjit (Sonny) Bal & Dana S. Bal
-----Signature
Bhajanjit (Sonny) Bal & Dana S. Bal
-----Print Name